Get started
Work

Supplemental Table S5 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens

Year: 2023
Type: supplementary-materials
Abstract: Plasma pharmacokinetics of tusamitamab ravtansine (cohort Q3W)
DOI: 10.1158/2767-9764.23834542
Authors: Josep Tabernero, Philippe L. Bedard, Yung-Jue Bang, Maria Vieito, Min-Hee Ryu, Nathalie Fagniez, Mustapha Chadjaa, Christine Soufflet, Nina Masson, Anas Gazzah
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4385554213
Cites:
Cited by:
Related to: 10